Pure Global
NCT06332170

ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors

ARTEMIS-101: A Phase 1, Open-label, Multi-center Study to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Administration of HS-20093 in Combination With Other Anti-cancer Agents in Patients With Advanced Solid Tumors
Hansoh BioMedical R&D Company·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumor
Drug/Device/Intervention
HS-20093
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Hansoh BioMedical R&D Company
Timeline & enrollment
Phase
Phase 1
Start date
May 30, 2024
End date
May 30, 2028
Enrollment
610 participants
Primary outcome

Maximum tolerated dose (MTD) for combination-treatments

Summary

HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to
 B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to
 investigate the safety, tolerability, pharmacokinetics and anti-tumor activity of HS-20093 in
 combination with other anti-cancer agents in patients with advanced solid tumor patients.

ICD-10 classifications
Carcinoma in situ, unspecifiedMalignant neoplasm: PrepuceMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm of other connective and soft tissue
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06332170
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06332170 through Pure Global AI's free database. This Phase 1 trial is sponsored by Hansoh BioMedical R&D Company and is currently Not yet recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 610 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.